Cell lines of human oral squamous-cell carcinomas retaining their differentiated phenotype

1990 ◽  
Vol 45 (5) ◽  
pp. 945-951 ◽  
Author(s):  
R. P. M. A. Crooijmans ◽  
J. H. M. Schwachöfer ◽  
J. Hoogenhout ◽  
G. Merkx ◽  
L. G. Poels ◽  
...  
2009 ◽  
Vol 40 (4) ◽  
pp. 256-263 ◽  
Author(s):  
Qiusha Tang ◽  
Jianqiong Zhang ◽  
Bing Qi ◽  
Chuanlai Shen ◽  
Wei Xie

2003 ◽  
Vol 82 (10) ◽  
pp. 802-806 ◽  
Author(s):  
K. Fukuchi ◽  
M. Date ◽  
Y. Azuma ◽  
M. Shinohara ◽  
H. Takahashi ◽  
...  

15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2) and troglitazone have been shown to induce apoptosis in several carcinoma cell lines. However, apoptotic signaling pathways of these agents are poorly understood. We tested the hypothesis that peroxisome proliferator-activated receptor-γ ligands such as these two agents will induce caspase-mediated apoptosis in human oral squamous cell carcinomas (SCC). Treatment of these cell lines with 15-d-PGJ2 or troglitazone decreased cell viability in a time- and dose-dependent manner. 15-d-PGJ2, but not troglitazone, induced apoptosis, and this effect was time-dependent. Exposure of cells to 20 μM of 15-d-PGJ2 initiated early cytochrome c release, followed by late caspase activation. Furthermore, co-treatment with caspase inhibitors such as Z-VAD-FMK or Z-DEVD-FMK of oral SCC cells that had been treated with 20 μM of 15-d-PGJ2 blocked apoptosis. Our study demonstrates that treatment with 15-d-PGJ2, but not troglitazone, induces apoptosis in human SCC cell lines, and 15-d-PGJ2 appears to work through cytochrome c release and caspase activation.


2007 ◽  
Vol 27 (6) ◽  
pp. 243-248 ◽  
Author(s):  
Yong-Kie Wong ◽  
Tsung-Yun Liu ◽  
Kuo-Wei Chang ◽  
Shu-Chun Lin ◽  
Tsurn-Waan Chao ◽  
...  

2019 ◽  
Vol 132 ◽  
pp. 38
Author(s):  
R. Waldram ◽  
A. Taylor ◽  
R. Prestwich ◽  
S. Whittam ◽  
L. Murray ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document